Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control
Cross-presenting Xcr1+CD8α DCs are attractive APCs to target for therapeutic cancer vaccines, as they are able to take up and process antigen from dying tumor cells for their MHCI-restricted presentation to CD8 T cells. To this aim, we developed fusion proteins made of the Xcr1 ligand Xcl1 fused to...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2019-02-01
|
| Schriftenreihe: | Frontiers in Immunology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00294/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|